banner
Company

SynGen Board Members

 

The SynGen Board Members include:

 


William Gerber, MD
Chairman

gerberWilliam Gerber, MD was an Investment Partner with Bay City Capital from 2005 to 2013, and he remains an active advisor to the firm. Prior to his role with Bay City Capital, he was President and Chief Executive Officer of Epoch BioSciences, which was acquired by Nanogen in 2004. Prior to Epoch, Dr. Gerber served as President and Chief Executive Officer of diaDexus LLC, a joint venture established by Incyte Pharmaceuticals and SmithKline Beecham to apply genomics to the discovery of novel diagnostic products. Dr. Gerber also served as Vice President and Chief Operating Officer of Onyx Pharmaceuticals, as President of Chiron Diagnostics, and as Senior Vice President and General Manager of the PCR Division of Cetus Corporation. Dr. Gerber is a member of the board of directors of Nabsys and Omicia. He also served on and was President of the Board of Medical Quality Assurance, State of California. He received his MD and BS degrees from University of California, San Francisco Medical Center after attending Dartmouth College.

 


George (Bud) Barry
Corporate Secretary and Co-Founder

George (Bud) Barry is an accomplished businessman with a successful track record in growing technology companies from start-up through IPO. He has more than 20 years of experience as a Chief Executive Officer or Chief Financial Officer for both private and public multinational technology companies His diverse background includes commercializing University technology research with KTEC, a quasi-public venture organization, and brokering the sale of a 32-facility dementia care business to the Hyatt corporation. Career highlights include driving private companies to a public offering and managing public company turnarounds.

While CEO at Mediware, Inc. (NASDAQ: MEDW), he released a new FDA-cleared product portfolio, organically grew cash from a net negative position to over $20 million, and increased enterprise value from under $15 million to over $140 million. The company received Investment Business Daily’s Top Stock Category and Mr. Barry was recognized with an Ernst & Young Entrepreneur of the Year award. He had similar success as the CFO/EVP of Comptek Research (AMEX: CTK) and Dynatech Corporation (NYSE: DYT).

Mr. Barry honed his strategic skill set through the direct management of over 30 M&A transactions including business integration, several public offerings, and numerous business partnering arrangements. He is a CPA and received his MBA from the University of Wisconsin, Madison.

Currently Mr. Barry, as co-founder of SynGen, is leading the finance, planning, and business strategy.

Carl Goldfischer, MD

Carl GoldfischerCarl Goldfischer, MD, is a Managing Director of Bay City Capital, and has been with the firm since 2000. He has invested across all subsectors within the life sciences industry and his expertise spans both private and public markets. In addition, he brings deep operational experience in finance, clinical trial development, and clinical medicine.

Dr. Goldfischer’s investments have included Cydan, EnteroMedics, Epizyme, MAP Pharmaceuticals, Nevro, Oculex Pharmaceuticals, PharmAkea, and SynGen.

Prior to joining Bay City Capital, Dr. Goldfischer was Chief Financial Officer of publicly traded biotech company ImClone Systems where he oversaw financial operations and strategic planning. Previously, he was a Health Care Research Analyst with the Reliance Insurance Company and was a Director of Research at D. Blech & Co. He began his career as a radiation oncologist at Montefiore Hospital, part of the Albert Einstein College of Medicine. Dr. Goldfischer received an MD with honors in Scientific Research from Albert Einstein College of Medicine and a BA from Sarah Lawrence College.

 


Vic Schmitt, MBA

schmittVic Schmitt, MBA has been a Venture Partner and Advisor to Bay City Capital since 2007.  He was formerly President, Venture Management, Baxter Healthcare Corporation where he  was responsible for the creation and management of Baxter Healthcare’s interests in development-stage biotech companies. Prior to this position, he held the operating position of President, Baxter Biotech Europe. He has also served as Vice President, Business Development and Finance for Baxter Healthcare’s Blood Therapy Group. Mr. Schmitt joined Baxter Healthcare from a sixteen-year career with the American Red Cross Blood Services. At the Red Cross Blood Services, he held positions in marketing and operations. At the time of his departure, he was Vice President, Blood Services with responsibility for the organization’s national blood services program. Mr. Schmitt holds a BS from the University of Virginia and an MBA from the University of Maryland. He has served on the board of directors of more than a dozen public and development-stage biotech companies.

 


Woodrow Myers, MD, MBA

myersDr. Woodrow Myers is a nationally recognized leader in the development of medical quality initiatives and advanced healthcare management programs. Today he serves as Chief Executive Officer for Corizon. This exciting challenge has coupled his passion for the highest standards of patient care and management, with the largest and most innovative correctional healthcare provider in the country.

Dr. Myers is a director at the Stanford University Hospital and Clinics, Express Scripts [ESRX], Valitás Health Services, Inc., SynGen, Inc., and serves on the Commercial Business Advisory Board for Third Rock Ventures, LLC. He is the Chairman of the Board of Directors of the Mozambique Healthcare Consortium (www.mozambiquehealth.org). Previously, he has served as the authorized representative for President Obama’s 2012 Re-Election Campaign, Obama for America, in the state of Indiana. He is the former executive vice president and chief medical officer of WellPoint, Inc., where he established the Health Quality Assurance Division. Dr. Myers also served as the director of healthcare management at the Ford Motor Company where he initiated quality assurance metrics for Ford healthcare vendors and established new global health and safety policies to benefit Ford and its employees. He is a former health commissioner for the city of New York and the state of Indiana, past chairman of the Visiting Committee for the Harvard School of Public Health and has served as a member of the Harvard University Board of Overseers and the Stanford University Board of Trustees. Additionally, he has served on several boards including Genomic Health [GHDX], LipoScience, Inc. [LPDX], PATH (Program for Appropriate Technology in Health), and Indiana Black Expo. He has received numerous awards and honors, and has made contributions to a large variety of journals, books, newspapers and online media.

Early in his career Dr. Myers was an assistant professor of medicine at the University of California San Francisco and a fellow in critical care medicine and a Robert Wood Johnson Foundation Clinical Scholar at the Stanford University Medical Center.

Dr. Myers received a doctor of medicine [MD] degree from the Harvard Medical School, a master’s degree in business administration [MBA] from the Stanford University Graduate School of Business, and a bachelor of science [BS] with honors from Stanford University.

He is married and has five children, one son-in-law, one-daughter-in-law, and two grand-children.